Multifocal IOLs as presbyopia treatment

Article

Implanting a multifocal intraocular lens (IOL) into the non-dominant eye is a promising treatment for presbyopic emmetropic patients, according to a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Implanting a multifocal intraocular lens (IOL) into the non-dominant eye is a promising treatment for presbyopic emmetropic patients, according to a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Dr Thomas Neuhann of the Augenklinik am Marienplatz, Munich, Germany evaluated monocular implantation of a multifocal diffractive apodized IOL (SN60D3, AcrySof ReSTOR Natural; Alcon) as a rehabilitative treatment for emmetropic and presbyopic patients (n=24).

Six months after unilateral implantation, all patients were found to have bilateral uncorrected near vision of 20/30; 83% of patients recorded uncorrected distance vision of 20/20. Half of patients remained spectacle-dependent for intermediate vision. A questionnaire determined overall patient satisfaction of 79% for near, intermediate and distance vision. One patient requested IOL implantation in the second eye.

Dr Neuhann concluded that unilateral IOL implantation offers a viable treatment option for sufferers of emmetropia and presbyopia.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.